Sinopharm Group HK$10 billion (US$1.3 billion) IPO
Bookrunners: CICC, Morgan Stanley, UBS
When it comes to China’s best capital markets deal it’s hard to look past Sinopharm’s Hong Kong listing last September.The deal stood out even in a year where there was a tidal wave of Chinese IPOs. ...
Please take a trial or subscribe to access this content.
Contact Mark Goodes to discuss your access: email@example.com